ARRY-649

ARRY-649 is an orally bioavailable, non-steroidal selective androgen receptor modulator (SARM) originally developed by Array BioPharma. It was engineered to exhibit tissue-selective activation of the androgen receptor, specifically targeting skeletal muscle and bone to promote anabolic effects while minimizing androgenic activity in tissues such as the prostate and sebaceous glands. This selectivity is intended to provide the therapeutic benefits of traditional anabolic steroids—such as increased muscle mass and bone density—without the associated side effects like virilization or prostate enlargement. ARRY-649 was primarily investigated in early-stage clinical trials for the treatment of muscle wasting (cachexia) associated with cancer and for improving functional recovery in elderly patients following hip fractures. Following the acquisition of Array BioPharma by Pfizer in 2019, the compound does not appear in the active clinical pipeline and is considered discontinued.